Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells-Reference-Cited by-同舟云学术

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

Published:2018-02-22 Issue:4 Volume:67 Page:533-540
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Park Jae H¹²³,Romero F Andres⁴,Taur Ying³⁴,Sadelain Michel³⁵⁶,Brentjens Renier J¹²³,Hohl Tobias M³⁴,Seo Susan K³⁴

Affiliation:

1. Leukemia Service, Memorial Sloan Kettering Cancer Center, New York

2. Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York

3. Department of Medicine, Joan and Sanford Weill Cornell Medical College, New York

4. Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York

5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

6. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York

Funder

National Institutes of Health

National Cancer Institute

American Society of Clinical Oncology

Leukemia and Lymphoma Society

National Comprehensive Cancer Network

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/4/533/25368355/ciy152.pdf

Reference32 articles.

1. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study;Fielding;Blood,2007

2. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies;Davila;Int J Hematol,2014

3. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia;Davila;Sci Transl Med,2014

4. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

5. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial;Lee;Lancet,2015

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature;The Lancet Infectious Diseases;2024-02

2. Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy;American Journal of Hematology;2024-01-10

3. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia;2024-01-02

4. High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma;HemaSphere;2024-01

5. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients;The Lancet Infectious Diseases;2024-01